Please login to the form below

Not currently logged in
Email:
Password:

EGFR mutation

This page shows the latest EGFR mutation news and features for those working in and with pharma, biotech and healthcare.

AstraZenca to appeal NICE rejection of Tagrisso

AstraZenca to appeal NICE rejection of Tagrisso

The drug is licensed in untreated locally-advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive NSCLC in the EU. ... NICE agreed that Tagrisso extends progression-free (PFS) and overall survival (OS) compared with first

Latest news

More from news
Approximately 1 fully matching, plus 47 partially matching documents found.

Latest Intelligence

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    There is a good reason why Tagrisso was chosen for the fast track – the drug is for patients with epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung ... The EGFR mutation is particularly prevalent in Asian populations

  • Harnessing complexity Harnessing complexity

    While more established methodologies still dominate, Next Generation Sequencing is starting to make an impact in the Oncology CDx world, as this breakdown of methodologies used for EGFR mutation testing in

  • Transforming times at AstraZeneca Transforming times at AstraZeneca

    It is a particularly pressing matter for AZ considering the company has several personalised medicines on market or in development, including Iressa (gefitinib) to treat lung cancer patients with a mutation ... in the EGFR-TK gene and Lynparza, which is

  • Diagnostics are rising up the pharma value chain Diagnostics are rising up the pharma value chain

    lung cancer, which was backed together with Roche Diagnostics' cobas EGFR Mutation Test. ... He adds: “What do we do when a person says they have a mutation of this type of cancer and there seems to be a drug.

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    If approved, the drug would complement AZ's other NSCLC drug, Iressa, which is approved in NSCLC patients with the EGFR mutation. ... Another development is AZD9291 – a drug which addresses the T790M mutation, which is a key resistance mechanism to

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics